Epigenic Therapeutics Raises $20 Million In Series Angel And Pre-A Funding To Advance Next Generation Gene Editing Therapy
Epigenic Therapeutics Raises $20 Million In Series Angel And Pre-A Funding To Advance Next Generation Gene Editing Therapy
08/06/22, 11:03 PM
Location
shanghaiMoney raised
$20 million
Industry
biotechnology
health care
genetics
therapeutics
Round Type
series a
Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured $20 million in Series Angel and Pre-A funding. Series Pre-A funding is jointly invested by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating.
Company Info
Location
shanghai, shanghai, china
Additional Info
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases. For more information, visit www.epigenictx.com